. This binding activates acid sphingomyelinase (ASM), an enzyme that breaks down the lipid sphingomyelin 7 , which is a typical and important component of cell membranes. Interestingly, increased ASM activity seems to support lysosomal integrity. Prompted by this observation, Petersen et al. hypothesized that inhibiting ASM in cancer cells would increase lysosomal fragility, LMP and cell death (Fig. 1) .
It was already known that cationic amphiphilic drugs (CADs) -substances that are well established for the treatment of depression, allergies and hypertension -act as ASM modulators. At the low pH of the lysosome, the drugs interfere with the electrostatic interaction between ASM, which is cationic, and the anionic surface of BMP-rich intralysosomal membranes 8, 9 . The displaced ASM is then rapidly degraded by cathepsins. Petersen and colleagues tested the effects of CAD treatment on several types of cancer cell, and found that the drugs killed the cells at much lower concentrations and shorter exposure times than was required for them to affect the viability of non-transformed cells. CAD treatment also led to reduced tumour growth in animal models. Furthermore, the authors found that cancer cells that were resistant to many other anticancer drugs were susceptible to CADs. Fascinatingly, this treatment restored the cells' susceptibility to the other drugs.
CANCER

Killing from the inside
Lysosomes are the main degradative compartment in cells, but they are also involved in cell-death pathways. Studies using existing drugs show that lysosomes are excellent pharmacological targets for selectively destroying cancer cells.
PA U L S A F T I G & KO N R A D S A N D H O F F
T here have been numerous efforts to identify the Achilles heel of cancer and to find ways of killing tumour cells while leaving normal cells un affected. The development of cancer chemo therapy started in the 1940s, and our increasing understanding of cancer biology has led to ever more precisely targeted therapies. Most of these strategies target the abnormal proliferative behaviour of cancer cells. Now, writing in Cancer Cell, Petersen et al. 1 propose an alternative intracellular anticancer target -the lysosome*.
For a long time, lysosomes were misleadingly regarded as the cell's waste bin, but we now know that they are more akin to cellular stomachs. In the lysosome, macromolecules are degraded by hydrolase enzymes, including protein-degrading cathepsin enzymes, and the resulting components are released as nutrients into the cytoplasm. Importantly, lysosomes are involved in several cellular processes, such as membrane repair, pathogen defence, autophagy and signalling 2 . The lysosomes in cancer cells are more numerous, larger and have greater cathepsin activity than those in normal cells, and the release of cathepsins from cancer-cell lysosomes into the extracellular space can promote tumour progression 3 . Lysosomes are also involved in cell death -the release of certain cathepsins from the lysosome into the cytoplasm is thought to trigger death by apoptosis and apoptosis-like pathways 4 . This release occurs by a process known as lysosome membrane permeabilization (LMP), which possibly occurs following certain changes to the composition of membrane lipids and major lysosomal membrane proteins 5 . LMP can be induced by various stimuli, including reactive oxygen species and endogenous apoptotic stimuli. However, cancer cells seem to overcome this threat of death by invoking the action of the protein Hsp70, which is expressed in many tumour types. Hsp70
Figure 1 | Lysosomes as a therapeutic cancer target. a, The degradation of macromolecules in lysosomes is achieved by hydrolase enzymes, including cathepsins. Another lysosomal enzyme is acid sphingomyelinase (ASM), which breaks down the membrane lipid sphingomyelin. ASM is positively charged and associates with another, negatively charged, lipid called BMP, which is found in the membranes of vesicles in the lysosome lumen. b, ASM activity is lower in cancer cells than in normal cells, and thus sphingomyelin levels are higher. Petersen and colleagues 1 show that cationic amphiphilic drugs (CADs) selectively kill cancer cells. CADs are positively charged, so they can displace ASM from vesicular membranes such that it is degraded by cathepsins. It is possible that this blocks the residual ASM activity in cancer cells, leading to even higher levels of sphingomyelin, which may disturb membrane homeostasis and cause lysosome membrane permeabilization (LMP). This allows cathepsins to be released into the cytoplasm, triggering cell-death pathways. 1 report a significant contribution to this field: the preparation of tube-shaped particles that attach to cells in different ways depending on the tubes' surface properties. This could lead to new ways to deliver drugs into target cells and to create constructs from cells.
Small particles (nanometres to micro metres in size) can interact with cells in many different ways, depending on the type of cell, the local environment and, notably, the physicochemical properties of the particles. Scientists and engineers are therefore working on approaches to tailor both the physical and the chemical properties of particles in order to develop control over their interactions with cells and tissues.
The size, stiffness, shape and chemical make-up of small particles all strongly influence how such particles interact with cells -they may bind to the outside of a cell, be taken up by the cell and trafficked through different pathways within it, and ultimately even change aspects of the cell's functions. Gilbert et al. have designed and made hollow, tubular, polymeric particles that can have non-uniform chemical properties, to see how this affected the particles' interactions with cells.
Gilbert et al. made the microtubes by assembling layers of oppositely charged polymers -polyelectrolytes -in the pores of a special type of filtration membrane that has straight pores. They then chemically cross-linked the polyelectrolytes to stabilize them, and dissolved away the membrane. Benefits of this method are that it can be used to make millions of microtubes at a time, and that it could be scaled up using multiple membranes. The dimensions of the microtubes could also be easily changed by altering the pore size or the thickness of the templating membrane.
The authors prepared microtubes that were either cell-resistant or cell-adhesive by changing the polymers used to make them. In a smart variation, they also made microtubes that were cell-resistant along their length on the outside but cell-adhesive inside. Because cells cannot fit inside the tubes, they can bind only to the ends of the microtubes where the adhesive molecules are exposed. The researchers therefore observed that these particles tend The reason for the high susceptibility of cancer cells to ASM targeting is not completely understood. However, it might be explained by the fact that ASM activity is already low in cancer cells, and a further decrease could lead to a membrane-destabilizing level of sphingomyelin in the lysosomes of these cells. Cancer cells have higher levels of membrane dynamics and cellular signalling than normal cells, and high concentrations of sphingomyelin might inhibit these processes. It is likely that other lipids that are ASM substrates also contribute to the fragility of lysosomal membranes in tumour cells. An additional aspect of the high sphingomyelin levels in cancer cells is that the export of cholesterol from lysosomes is inhibited 10 ; this leads to the inactivation of saposins (essential cofactors for sphingolipid-degrading enzymes), and thereby a further reduction in sphingolipid degradation.
Thus, it seems that CAD treatment may lead to a generally dysfunctional lysosomal-lipid homeostasis that severely affects the physiology of this cellular compartment and favours lysosome-related cell-death pathways. It would be useful to analyse the specificity of CADs for tumour-cell targeting in genetically defined animal models, such as mice lacking or overexpressing ASM. Another aspect yet to be investigated is the rate of uptake of CADs in tumour cells compared with healthy cells. Surprisingly, although the events following LMP are well understood, a long-standing question is how LMP is mediated at a molecular level. Further studies of the role of CADs may help to explain how alterations in the lipid or protein composition of lysosomal membranes lead to transient and enzyme-specific lysosomal leakage.
Despite these remaining questions, Petersen and colleagues' findings argue for an in-depth pharmacological and epidemiological study of the effect of CAD treatment on cancer outcomes. CADs are relatively cheap drugs that have limited side effects, but their activity in lysosomal killing pathways is probably not sufficient for effective cancer therapy when used alone, so combination treatments with other chemotherapeutic compounds might be advisable. Future research might also reveal specific and potent modulators of lysosomal-sphingolipid metabolism that are even more effective than CADs at inducing the death of cancer cells through this pathway. ■ 
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